Mohanty Triyambakesh, Kumar Sujeet, Rout Sunil Swick, Kar Sarita, Bal Himadri Bhusan, Turuk Jyotirmayee, Das Dasarathi, Sundaray Sooman, Pati Sanghamitra, Giri Sidhartha
National Reference Laboratory for TB, ICMR-Regional Medical Research Centre, Bhubaneswar, 751023, Odisha, India.
ICMR-Regional Medical Research Centre, Bhubaneswar, 751023, Odisha, India.
Indian J Med Microbiol. 2023 Nov-Dec;46:100479. doi: 10.1016/j.ijmmb.2023.100479. Epub 2023 Oct 4.
We conducted a retrospective study to evaluate the burden of tuberculosis and rifampicin resistance in patients with pleural effusion in Bhubaneswar, Odisha, during February 2016, to December 2022, using cartridge-based nucleic acid amplification test (CBNAAT, Xpert MTB/RIF). Of the 1370 pleural fluid samples tested at the National Reference Laboratory for tuberculosis, 3.8% (52/1370) were positive for M.tuberculosis. Rifampicin resistance was detected in 3.8% (2/52) samples. The positivity was 5% in 2016, increased to 7.5% in 2020, and was 4.4% in 2022. The positivity varied across age groups, ranging from 1.5% in patients aged >60 years to 6.1% in 15-30 years.
我们开展了一项回顾性研究，以评估2016年2月至2022年12月期间在奥里萨邦布巴内斯瓦尔患有胸腔积液的患者中结核病和利福平耐药性的负担，采用基于 cartridge 的核酸扩增试验（CBNAAT，Xpert MTB/RIF）。在国家结核病参考实验室检测的1370份胸腔积液样本中，3.8%（52/1370）的样本结核分枝杆菌呈阳性。在3.8%（2/52）的样本中检测到利福平耐药性。2016年阳性率为5%，2020年增至7.5%，2022年为4.4%。阳性率在不同年龄组中有所不同，年龄>60岁的患者为1.5%，15 - 30岁的患者为6.1%。
